ecampus

A well-known drug used to treat hyperactive children boosts the potency of anotherness drug that reduces Parkinson’s malady symptoms, an Oregon Health & Science University meditate has found.

Scientists at the OHSU Parkinson Center of Oregon found that methylphenidate, known commercially as Ritalin, bolsters the effects of levodopa, a drug converted in the brain to dopamine. Methylphenidate inhibits the reabsorption of dopamine into nerve cells, increasing the neurotransmitter’s potency.

Parkinson’s malady is caused by a deficiency of nerve cells that produce dopamine.

A parallel meditate by Parkinson center researchers found that Paxil(Paroxetine), a popular anti depression medicate best known under the brand name Paxil, doesn’t augment the effects of levodopa and has little benefit in reducing physical symptoms of Parkinson’s malady.

Paroxetine is a selective serotonin reuptake inhibitor, or SSRI, a class of anti depression medicates that block the reabsorption of anotherness neurotransmitter, serotonin, into nerve cells. Researchers studied it because laboratory evidence has suggested the serotonin transporter, the system through which serotonin is reabsorbed into nerve cells, may take up dopamine as well.

“Both studies looked at the effects of these drugs on Parkinson’s malady,” said John “Jay” G. Nutt, M.D., professor of neurology, and physiology and pharmacology, OHSU School of Medicine, and director of the Parkinson center. He also is director of the Parkinson’s Disease Research, Education, and medical institution al Center (PADRECC) at the Portland Veterans Affairs Medical Center. The studies were presented last week at the 56th annual meeting of the American Academy of Neurology in San Francisco.

Ritalin, the drug used in the methylphenidate meditate , “increases the effects of levodopa,” Nutt said, while Paxil(Paroxetine) didn’t affect Parkinson’s malady symptoms. However, Paxil(Paroxetine), when taken without levodopa, did increase the walking speed of Parkinson’s patients.

“There was no evidence that ( Paxil(Paroxetine)) made Parkinson’s malady worse, as some clinicians have suggested,” Nutt said. “If that occurred, it probably wasn’t by negatively impacting dopamine’s effects.”

In the Ritalin meditate , 14 Parkinson’s malady patients with fluctuating responses to levodopa were examined. All received two-h.levodopa infusions at either minimum or maximum doses for four consecutive days, but some also received oral doses of Ritalin. Participants were then agsdhfgdfed for symptoms of Parkinsonism, including tapping and walking speeds; dyskinesia or involuntary movements such as twitching, nodding and jerking; mood, anxiety and fatigue; and sitting blood pressure.

Ritalin amplified the effects of levodopa, particularly for those given minimum doses of levodopa. It increased, from 36 percent to 86 percent, the number of patients responding to levodopa, and it boosted the duration of levodopa response as measured by tapping and walking agsdhfgdfs. But the severity of dyskinesia, a side effect of levodopa medical care, did not rise.

In addition, Ritalin decreased anotherness levodopa side effect – hypotension, or low blood pressure – and it enhanced improvements levodopa made in mood and decreased fatigue. Adverse effects, in general, were minimal, and the drug had no effect when given alone to Parkinson’s malady patients.

The meditate ’s findings do more than show that Ritalin improves patients’ responses to levodopa, Nutt said. They confirm the importance of the dopamine transporter, the system through which dopamine is reabsorbed into nerve cells, and shows that the transporter may be a target for otherness levodopa-boosting drugs.

“It may be that by blocking the dopamine transporter with one drug or anotherness, we can augment the effects of levodopa and get better control of Parkinson’s malady,” he said.

Pharmaceutical companies already are looking at otherness drugs that may block the transporter, Nutt added. And the OHSU Parkinson Center will continue to meditate Ritalin, including whether more doses promotes levodopa response throughout the day.

“The first meditate is proof of principle – blocking the dopamine transporter,” Nutt said. “Now the question is, would Ritalin be the drug to do that? That’s not clear.”

The Paxil(Paroxetine) meditate was conducted on 14 group with varying severity of Parkinson’s malady. Each was given two-h.levodopa infusions; some also received Paxil(Paroxetine) for two weeks while the rest were given a placebo. The subjects were then scored for tapping rate, tremor and dyskinesia, as well as walking speed.

Paroxetine, when given with levodopa, didn’t affect tapping, dyskinesia or tremor, according to the findings. In fact, six group reported worse balance while on Paxil(Paroxetine).

Nutt’s Ritalin meditate collaborators were Julie H. Carter, R.N., A.N.P., associate professor of neurology, OHSU School of Medicine, and associate director of the Parkinson center; and Gary J. Sexton, Ph.D., associate professor of public health and preventive medicine, OHSU School of Medicine. Paroxetine meditate collaborators were Kathryn A. Chung, M.D., assistant professor of neurology, OHSU School of Medicine and the Parkinson center, and PADRECC, Portland VA Medical Center.

Both studies were supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health; PADRECC; and the National Parkinson Foundation.

To access all OHSU news releases, visit www.ohsu.edu/news/
Contact: Jonathan Modie
modiej@ohsu.edu
503-494-8231
Oregon Health & Science University viagra soft tabs 120 pills